Wordt geladen...
Opportunities and challenges for antisense oligonucleotide therapies
Antisense oligonucleotide (AON) therapies involve short strands of modified nucleotides that target RNA in a sequence‐specific manner, inducing targeted protein knockdown or restoration. Currently, 10 AON therapies have been approved in the United States and Europe. Nucleotides are chemically modifi...
Bewaard in:
| Gepubliceerd in: | J Inherit Metab Dis |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley & Sons, Inc.
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7891411/ https://ncbi.nlm.nih.gov/pubmed/32391605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jimd.12251 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|